Matrix Laboratories Limited

Indukuri Venkata Sunil Kumar

Gorantla Seeta Ramanjaneyulu

Chava Satyanarayana

Jammula Vera Venkata Krishna Kishore

Ketavarapu Narasimha Rao

A cost-effective, industrially feasible process for the manufacture of crystalline Carvedilol Form-II using novel Carvedilol salts comprises the steps of reacting 4-(2,3-epoxy propoxy)carbazole (II) with 2-(2-methoxy phenoxy)ethyl amine (III) followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, treatment of the said salts with base(s) in presence of organic solvent(s), water and isolation from the organic solvent(s) followed by crystallization from ethyl acetate.

Process for the preparation of Carvedilol Form II

The present invention relates to a process for purification of novel polymorphic form of Gatifloxacin which comprises dissolving Gatifloxacin in about 15-50 volumes of methanol, removing insolubles if any, adding organic base to the solution, maintaining the solution at temperature of 30&#xb0; C. to 70&#xb0; C., for about 20 min to 4 hrs, followed by gradual cooling and maintaining the reaction mass to &#x2212;10 to 20&#xb0; C. for about 1-4 hrs, isolation and drying at temperature of about 45&#xb0; C. to 65&#xb0; C.

Crystalline forms of Gatifloxacin

The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline Carvedilol Form-II using novel Carvedilol salts comprising a step of reacting 4-(2,3-epoxy propoxy)carbazole (II) with 2-(2-methoxy phenoxy)ethyl amine (III) followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, treatment of the said salts with base(s) in presence of organic solvent(s), water and isolation from the organic solvent(s) followed by crystallization from ethyl acetate.

Process for the preparation of carvedilol form-II

The present invention relates to a new industrial feasible process for the preparation of Gabapentin Form-II via a novel intermediate Gabapentin hemisulphate hemihydrate with out forming Gabapentin Form-III by neutralizing the Gabapentin hemisulphate hemihydrate solution with a base at higher temperatures followed by cooling to yield Gabapentin Form II with sulphate ions less than 100 ppm with respect to Gabapentin.

Growing community of inventors

Hyderabad Telangana, India

Indukuri Venkata Sunil Kumar